TRAX — First Tracks Biotherapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 2091349 ·
Last close
$34.42
Market Cap
$1.23B
52W High
$49.91
52W Low
$14.72
ADV30
674,650
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -34,937,000 | -33,374,000 | 183,140,000 | 168,018,000 | 14,344,000 |
| Mar 2026 | 0 | — | -52,811,000 | -50,484,000 | 290,576,000 | 248,469,000 | 33,112,000 |
| Jun 2025 | 0 | — | -45,898,000 | -42,445,000 | — | — | — |
| Mar 2025 | 0 | — | -51,280,000 | -47,196,000 | — | — | — |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-77,567,000
Investing CF
$49,830,000
Financing CF
$13,567,000
CapEx
$-52,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.81
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
—
Inventory
—
Receivables
—
ST Investments
$37,986,000
EBIT TTM
$-104,091,000
Pretax Income TTM
$-97,680,000
Interest Exp TTM
—
Analysts
8
Annual Trend (SEC EDGAR, last 2y)
Revenues vs Net Income (last 2y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2024 | 0 | -181,101,000 | -163,705,000 | 441,891,000 | 50,295,000 | 391,596,000 | -125,806,000 |
| Dec 2023 | 0 | -118,461,000 | -106,150,000 | 444,109,000 | 34,260,000 | 409,849,000 | -93,004,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-3.66
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $20.00 · spot: $36.65 · call volume: 298 · put volume: 4Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| OPK | OPKO HEALTH, INC. | $1.22B | $1.64 | — |
| HROW | HARROW, INC. | $1.24B | $33.07 | — |
| AVLN | Avalyn Pharma Inc. | $1.24B | $28.08 | — |
| LBRX | LB PHARMACEUTICALS INC | $1.20B | $37.33 | — |
| BCAX | Bicara Therapeutics Inc. | $1.27B | $19.21 | — |
News headlines (Yahoo Finance, 1h cache)
Rosnilimab Emerges as a Potential Advance in Rheumatoid Arthritis as Physicians Look to the Next Wave of Pipeline Innovation
2026-09-10 12:52 · Yahoo
First Tracks Biotherapeutics Announces Participation in September Investor Conferences
2026-08-26 20:15 · Yahoo
First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update
2026-08-12 20:15 · Yahoo
TRAX Stock Hits All-Time High — What's Driving The Super Rally?
2026-07-10 16:14 · Yahoo
First Tracks Biotherapeutics Announces First Quarter 2026 Financial Results and Provides Business Update
2026-05-14 20:15 · Yahoo
AnaptysBio (ANAB) Reports a Tax-Driven Profit. When Will Royalties Fund Shareholder Returns?
2026-09-26 03:38 · Yahoo
Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update
2026-05-12 20:15 · Yahoo
Assessing AnaptysBio (ANAB) Valuation After Royalty Pivot Spinoff And Legal Outcome
2026-05-11 01:10 · Yahoo
Is AnaptysBio (ANAB) One of the Best Performing Healthcare Stocks so Far in 2026?
2026-05-10 23:13 · Yahoo
First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences
2026-05-21 20:15 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.